Search: onr:"swepub:oai:lup.lub.lu.se:9cb45039-4e72-4793-8584-0a7fa98e0ad0" >
Oral contraceptives...
-
Brohet, Richard M.
(author)
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group
- Article/chapterEnglish2007
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:9cb45039-4e72-4793-8584-0a7fa98e0ad0
-
https://lup.lub.lu.se/record/657236URI
-
https://doi.org/10.1200/JCO.2007.11.1179DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Purpose Earlier studies have shown that endogenous gonadal hormones play an important role in the etiology of breast cancer among BRCA1/ 2 mutation carriers. So far, little is known about the safety of exogenous hormonal use in mutation carriers. In this study, we examined the association between oral contraceptive use and risk of breast cancer among BRCA1/ 2 carriers. Patients and Methods In the International BRCA1/ 2 Carrier Cohort study ( IBCCS), a retrospective cohort of 1,593 BRCA1/ 2 mutation carriers was analyzed with a weighted Cox regression analysis. Results We found an increased risk of breast cancer for BRCA1/ 2 mutation carriers who ever used oral contraceptives ( adjusted hazard ratio [ HR] = 1.47; 95% CI, 1.16 to 1.87). HRs did not vary according to time since stopping use, age at start, or calendar year at start. However, a longer duration of use, especially before first full- term pregnancy, was associated with an increased risk of breast cancer for both BRCA1 and BRCA2 mutation carriers ( 4 or more years of use before first full-term pregnancy: HR = 1.49 [ 95% CI, 1.05 to 2.11] for BRCA1 carriers and HR = 2.58 [ 95% CI, 1.21 to 5.49] for BRCA2 carriers). Conclusion No evidence was found among BRCA1/ 2 mutation carriers that current use of oral contraceptives is associated with risk of breast cancer more strongly than is past use, as is found in the general population. However, duration of use, especially before first full- term pregnancy, may be associated with an increasing risk of breast cancer among both BRCA1 and BRCA2 mutation carriers.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Goldgar, David E.
(author)
-
Easton, Douglas F.
(author)
-
Antoniou, Antonis C.
(author)
-
Andrieu, Nadine
(author)
-
Chang-Claude, Jenny
(author)
-
Peock, Susan
(author)
-
Eeles, Rosalind A.
(author)
-
Cook, Margaret
(author)
-
Chu, Carol
(author)
-
Nogues, Catherine
(author)
-
Lasset, Christine
(author)
-
Berthet, Pascaline
(author)
-
Meijers-Heijboer, Hanne
(author)
-
Gerdes, Anne-Marie
(author)
-
Olsson, HåkanLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-hol
(author)
-
Caldes, Trinidad
(author)
-
van Leeuwen, Flora E.
(author)
-
Rookus, Matti A.
(author)
-
Medicinsk onkologiSektion I
(creator_code:org_t)
Related titles
-
In:Journal of Clinical Oncology25:25, s. 3831-38361527-7755
Internet link
Find in a library
To the university's database
- By the author/editor
-
Brohet, Richard ...
-
Goldgar, David E ...
-
Easton, Douglas ...
-
Antoniou, Antoni ...
-
Andrieu, Nadine
-
Chang-Claude, Je ...
-
show more...
-
Peock, Susan
-
Eeles, Rosalind ...
-
Cook, Margaret
-
Chu, Carol
-
Nogues, Catherin ...
-
Lasset, Christin ...
-
Berthet, Pascali ...
-
Meijers-Heijboer ...
-
Gerdes, Anne-Mar ...
-
Olsson, Håkan
-
Caldes, Trinidad
-
van Leeuwen, Flo ...
-
Rookus, Matti A.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Journal of Clini ...
- By the university
-
Lund University